Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the second IgA nephropathy (IgAN) dose cohort in RUBY-3, a phase 1b/2a study in autoimmune glomerulonephritis. The safety Monitoring Committee (SMC) determined that repeat . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain has approved Roche's (

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product has been game changer in the treatment of various difficult to treat cancers before the products that target PD-L1 and approved for several various  cancers were developed by MRK and BMY.     Exelixis (EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data . . . …

Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer and chronic inflammatory diseases, and other diseases. In partnership with firms and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways while studying novel, biology-driven . . . This content is for paid …

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for EYLEA HD is 8 mg . . . This content is for paid subscribers. Please click here to subscribe or …

Nuvectis Pharma Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs capable of treating cancers that have yet to find treatments. The Company’s pipeline comprises two drug candidates, NXP800 and NXP900. NXP800  is an oral small molecule in Phase 1b clinical investigating the product activity and potential treatment of platinum resistant ARID1a-mutated ovarian carcinoma . . . This content is …

Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. FDA has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), which no longer responds to androgen deprivation therapy and has spread to other …

Xenon Pharmaceuticals Q2 Financial Results On  August 09, 2023 , Xenon Pharmaceuticals (XENE) reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. Xenon report started with Mr. Ian Mortimer, the firm’s President and Chief Executive Officer, stating, “We are pleased to announce that patient enrollment is complete in our XEN1101 Phase 2 “X . . . This content is for paid …

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM  TODAY CymaBay Therapeutics, Inc. (CBAY) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic diseases with high unmet need, announced that it will host a conference call and live audio webcast Today, Thursday . . . This content is for paid …